BSD Medical recently announced that its BSD-2000 Hyperthermia System has been purchased by the prestigious University of California San Francisco Medical Center. The system will now be available as a treatment option for the center’s patients.
One of the top 10 hospitals in the U.S., UCSF Medical Center is recognized around the world for its advanced patient care and cutting-edge technology. The center is one of the leading cancer care providers in the world. UCSF Medical Center’s Comprehensive Cancer Center was awarded the prestigious “comprehensive” designation from the National Cancer Institute and ranks sixth in the nation in NCI research grants. UCSF Medical Center employs more than 7,000 people at its numerous facilities.
UCSF has a longstanding history of providing cutting-edge therapies to patients. The center also recently purchased a BSD-500 Hyperthermia System from BSD Medical Corporation, and the company is pleased they will also be offering the BSD-2000’s pioneering capabilities to their patients.
The BSD-2000, which has been exclusively developed and patented by BSD, provides localized therapeutic heating (hyperthermia) through the application of radiofrequency (RF) energy. The system creates a central focus of energy that is capable of electronically focusing to target the shape, size, and location of a tumor, thereby providing dynamic control of the heating delivered to the tumor region. The system has Humanitarian Device Exemption (HDE) marketing approval from the FDA for use in conjunction with radiation therapy to treat cervical cancer patients who are not eligible for chemotherapy. Additionally, the BSD-2000 has CE Marking approval for commercial sale in Europe and many countries outside of the European Union.
BSD Medical Corporation is engaged in the development, manufacturing, marketing, and servicing of systems for the treatment of cancer and benign diseases by means of heat therapy delivered via RF and microwave energy. The company’s product lines include systems for treating both hyperthermia and ablation.
In use for several years in the U.S., Europe, and Asia, BSD’s hyperthermia cancer treatment systems are used for treating certain tumors with heat (hyperthermia) while simultaneously increasing the effectiveness of other therapies like radiation therapy. The company’s microwave ablation system has been developed as a standalone therapy for employing precision-guided microwave energy to destroy soft tissue.
BSD has developed substantial intellectual property and multiple products in the market, and the company has established distribution in the U.S., Europe, and Asia. Some of the company’s products have been granted regulatory approvals and clearances in the U.S., Europe, and China.
For more information, visit the company’s Web site at www.BSDMedical.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
